Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC 704865) in Patients With Advanced Nonsquamous NSCLC.

Trial Profile

Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC 704865) in Patients With Advanced Nonsquamous NSCLC.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Results assessing post-progression survival of PointBreak, ARIES and ECOG 4599 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 01 Sep 2010 Results based on histologic subtype were published in the Journal of Thoracic Oncology.
    • 13 May 2009 Lead trial investigator (Lenz H-J) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top